The global geothermal heat pumps market players are struggling to achieve a steady and noticeable position in the market through product improvement while the level of rivalry amongst them is extreme. The global geothermal heat pumps mar…
BMI View: Switzerland will remain amongst the wealthiest countries in the world in real GDP per capita
terms, which together with an aging population and a preference for patented medicines, will keep
pharmaceutical spending high. However, faced with growing healthcare costs, the Swiss government will to
continue to enforce measures that restrict growth in medicine sales - including the roll-out of initiatives that
enforce the cost effective pricing and rational prescribing of medicines.
Headline Expenditure Projections
? Pharmaceuticals: CHF7.07bn (USD7.34bn) in 2015 to CHF7.08bn (USD6.89bn) in 2016; +0.25% in
local currency terms and -6.1% in US dollar terms.
? Healthcare: CHF73.68bn (USD76.55bn) in 2015 to CHF75.45bn (USD73.39bn) in 2016; +2.4% growth
in local currency terms and -4.1% in US dollar terms.
Switzerland's Pharmaceutical Risk/Reward Index score for Q416 stands at 73.1 out of a total of 100, above
the regional average of 70.6. High per-capita spending on medicines, as well as a growing demand for
medicines as a result of the country's ageing population, makes Switzerland an attractive market in which to
launch innovative medicines. However, the government's focus on cost containment within the
pharmaceuticals and healthcare sector will continue to pose challenges to drug companies.
? In 2015, in volume terms, 58% of all medicine packs sold in Switzerland were reimbursable,
experiencing a 2.9% increase over 2014 volumes.
? In 2015, sales of medicines for the treatment of the central nervous system accounted for the largest
market share at 14.5%.
? In 2015, the 24 Interpharma companies spent more than CHF6.9bn in research and development (R&D)